Humanized IgG1 monoclonal antibody against EGFR; binds EGFR to block ligand-induced activation, inhibiting downstream RAS/RAF/MEK/ERK and PI3K/AKT signaling, and may elicit ADCC.
Humanized IgG1 monoclonal antibody against EGFR that blocks ligand-induced receptor activation and downstream RAS/RAF/MEK/ERK and PI3K/AKT signaling, and may elicit ADCC to inhibit tumor growth.
YES
DIRECT
IgG1 anti-EGFR antibody binds EGFR on target cells and engages Fcγ receptor–bearing effector cells (e.g., NK cells) to mediate ADCC, killing the EGFR-expressing cells; it also blocks EGFR signaling (growth inhibition).
Anti-GD2 IgG1 monoclonal antibody that mediates ADCC and complement-dependent cytotoxicity against GD2-positive tumor cells.
Chimeric IgG1 anti-GD2 monoclonal antibody that binds GD2 on tumor cells and triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, resulting in lysis of GD2-positive cells.
YES
DIRECT
Binds GD2 on target cells and triggers Fc-mediated ADCC (e.g., NK cells/macrophages) and complement-dependent cytotoxicity, causing lysis of GD2-positive cells.
An intravenous bispecific T-cell engager (BiTE) antibody (AMG 757; IMDELLTRA) that binds DLL3 on SCLC tumor cells and CD3 on T cells, creating an immune synapse to activate TCR/CD3 signaling and redirect T-cell cytotoxicity against DLL3-expressing cells.
Bispecific T-cell engager antibody that binds DLL3 on tumor cells and CD3 on T cells, creating an immune synapse that activates TCR/CD3 signaling and redirects T-cell cytotoxicity to kill DLL3-expressing cells (e.g., SCLC).
YES
DIRECT
Bispecific T-cell engager binds DLL3 on target cells and CD3 on T cells, forming an immune synapse that activates TCR/CD3 signaling and triggers perforin/granzyme-mediated killing of DLL3-expressing cells.
Investigational intravenous immunotherapy evaluated as monotherapy in a first-in-human Phase 1 dose-escalation/expansion trial in metastatic castration-resistant prostate cancer; exact target and mechanism undisclosed.
Dual-targeting antibody–drug conjugate against PSMA and STEAP1. Upon binding these antigens on tumor cells, the complex is internalized and an undisclosed cytotoxic payload is released intracellularly, inducing tumor cell death; the exact payload and cytotoxic mechanism are not disclosed.
YES
DIRECT
An ADC binds PSMA on tumor cells, is internalized, and releases an intracellular cytotoxic payload that kills the cell.
Investigational intravenous immunotherapy evaluated as monotherapy in a first-in-human Phase 1 dose-escalation/expansion trial in metastatic castration-resistant prostate cancer; exact target and mechanism undisclosed.
Dual-targeting antibody–drug conjugate against PSMA and STEAP1. Upon binding these antigens on tumor cells, the complex is internalized and an undisclosed cytotoxic payload is released intracellularly, inducing tumor cell death; the exact payload and cytotoxic mechanism are not disclosed.
YES
DIRECT
As an ADC, ABBV-969 binds STEAP1 on the cell surface, is internalized, and releases an (undisclosed) cytotoxic payload inside the cell, leading to target cell death.